Microdosing Tirzepatide Injection

Tirzepatide activates two complementary hormone pathways—GIP and GLP-1 receptors. These pathways influence appetite regulation, insulin signaling, and digestive speed. By supporting both systems, tirzepatide may help reduce hunger cues, increase fullness after meals, and support healthier metabolic signaling over time.


Microdosing is a low-dose strategy: a clinician keeps the dose below standard weight-loss dosing and fine-tunes it within that low range to balance comfort with progress, not up to a full dose.

Use tirzepatide exactly as prescribed. It is typically administered as a subcutaneous injection once weekly, on the same day each week, with or without food.


Common injection sites include:

• Abdomen (stomach area)
• Thigh
• Upper arm

Rotate injection sites and avoid injecting into skin that is tender, bruised, red, or hard. Your clinician may adjust dosing over time to support tolerability and results. If you miss a dose or have questions about timing, contact your care team.

‍

Tirzepatide may cause side effects. The most commonly reported include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Stomach discomfort
• Decreased appetite
• Injection-site reactions

Side effects are often most noticeable when starting treatment or changing dose. A gradual, clinician-guided approach may help improve tolerability for some people. Seek medical attention for severe or persistent symptoms, signs of an allergic reaction, or severe abdominal pain.